Moderna
MRNA
#1830
Rank
HK$84.25 B
Marketcap
HK$215.63
Share price
8.67%
Change (1 day)
-35.47%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.

Revenue for Moderna (MRNA)

Revenue in 2025 (TTM): HK$17.12 Billion

According to Moderna 's latest financial reports the company's current revenue (TTM ) is HK$17.14 Billion. In 2024 the company made a revenue of HK$24.83 Billion a decrease over the revenue in the year 2023 that were of HK$52.74 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Moderna from 2018 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) HK$17.12 B-31.04%
2024 HK$24.83 B-52.92%
2023 HK$52.74 B-64.23%
2022 HK$147.47 B6.64%
2021 HK$138.29 B6401.99%
2020 HK$2.12 B468.55%
2019 HK$0.37 B-61.09%
2018 HK$0.96 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Regulus Therapeutics
RGLS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
HK$500.04 B 2,817.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
HK$0.62 M-100.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
HK$24.98 B 45.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
HK$438.83 B 2,460.04%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Arrowhead Pharmaceuticals
ARWR
HK$4.46 B-73.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
HK$717.34 B 4,084.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
HK$1.50 B-91.24%๐Ÿ‡บ๐Ÿ‡ธ USA